Receptor News and Research

RSS

Palbociclib drug shows promise in women with HR+ metastatic breast cancer

Despite advances in managing and curing some forms of breast cancer, women whose disease becomes metastatic have fewer effective options. A new phase 3 study in some of the most difficult-to-treat patients, women with endocrine-resistant disease, showed that the newly approved drug, palbociclib, more than doubled the time to cancer recurrence for women with hormone-receptor (HR+) positive metastatic breast cancer.

30 May 2015

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Astellas Pharma Inc. today announced that preliminary data from a Phase 1/2 trial on the safety, tolerability and efficacy of ASP2215, a selective inhibitor of FLT3/AXL, in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) were presented during an oral abstract session at the American Society of Clinical Oncology's annual meeting in Chicago.

30 May 2015

BioDelivery Sciences calls for new treatment options for opioid addiction

As the rate of opioid abuse soars to new levels, growing recognition of the problem is garnering unprecedented media attention—as well as motivating innovative new approaches to better treatment.

30 May 2015

RPCI-led research team to share clinical results of entolimod drug at ASCO 2015

A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute (RPCI) will share results from the first clinical study of the anticancer effects of the novel agent entolimod at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting in Chicago.

30 May 2015

Researchers discover new source for cells that can develop into coronary vessels

The heart has its own dedicated blood supply, with coronary arteries that supply oxygen-rich blood to the heart and cardiac veins that remove deoxygenated blood. This system of vessels nourishes the heart, enabling it to pump blood to all the other organs and tissues of the body. Yet despite their critical importance, the process and molecules required for coronary vessel development have not been fully determined.

30 May 2015

MD Anderson Cancer Center's Jim Allison to receive Science of Oncology Award at ASCO 2015

The world's leading organization of oncologists will honor Jim Allison, Ph.D., for his pioneering research that led to a new way to treat cancer by unleashing an immune system attack rather than targeting tumors directly.

30 May 2015

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology.

30 May 2015

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Data to be presented at the 51st Annual Meeting of the American Society of Clinical Oncology suggest that the investigational immunotherapy MPDL3280A may double the likelihood of overall survival in the study period (HR=0.47), compared with docetaxel chemotherapy, in individuals with non-small cell lung cancer (NSCLC) who expressed the highest levels of PD-L1 (a receptor present on cancer cells).

30 May 2015

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

BerGenBio AS, an oncology biopharmaceutical company, today announces that an abstract on the latest data on BGB324, the Company's first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published in conjunction with the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29 - June 2, 2015.

30 May 2015

Patient characteristics may guide TKI use in CML

The likelihood of complications associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia may be reduced by considering patient factors and differences in the toxicity profiles of the different drug options, a review suggests.

29 May 2015

Airway granulocytes potential CF biomarker for fungal lung disease

Researchers have found that accumulation in the airways of CXCR4+ granulocytes is associated with chronic colonisation by the fungus Aspergillus fumigatus.

29 May 2015

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating the range of treatment options represented in Lilly's diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston.

29 May 2015

Differences in brain expression of RORA protein levels may lead to sex bias in autism

George Washington University researcher Valerie Hu, Ph.D., has found an important sex-dependent difference in the level of RORA protein in brain tissues of males and females. Specifically, females without autism have a slightly higher level of RORA in the frontal cortex of the brain than males without autism, while the levels of the protein are comparably lower in the brain of both males and females with autism.

29 May 2015

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen today announced pooled data from two pivotal Phase 3, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) receiving hemodialysis.

29 May 2015

Monoclonal antibody nivolumab improves survival rates of melanoma patients

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.

29 May 2015

Novel discovery offers new insight into why women more likely than men to develop MS

An innocent mistake made by a graduate student in a Northwestern Medicine lab (she accidentally used male mice instead of female mice during an experiment) has led scientists to a novel discovery that offers new insight into why women are more likely than men to develop autoimmune diseases such as multiple sclerosis (MS).

28 May 2015

UB researchers identify mechanisms behind some autistic behaviors, suggest potential targets

Scientists at the University at Buffalo have identified the mechanisms behind a genetic mutation that produces certain autistic behaviors in mice, as well as therapeutic strategies to restore normal behaviors.

28 May 2015

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

A new collaborative study led by researchers at Sanford-Burnham Medical Research Institute, published today in Cell Reports, provides new insight into the molecular changes that lead to resistance to a commonly prescribed group of drugs called BRAF inhibitors.

28 May 2015

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Biscayne Pharmaceuticals, Inc., today announced that data supporting the anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology will be discussed in a poster presentation at the 2015 ASCO Annual Meeting.

28 May 2015

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Actavis plc announced today that VIBERZI (eluxadoline) was approved by the Food and Drug Administration as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist.

28 May 2015

Receptor News and Research

Palbociclib drug shows promise in women with HR+ metastatic breast cancer

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

BioDelivery Sciences calls for new treatment options for opioid addiction

RPCI-led research team to share clinical results of entolimod drug at ASCO 2015

Researchers discover new source for cells that can develop into coronary vessels

MD Anderson Cancer Center's Jim Allison to receive Science of Oncology Award at ASCO 2015

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

Patient characteristics may guide TKI use in CML

Airway granulocytes potential CF biomarker for fungal lung disease

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

Differences in brain expression of RORA protein levels may lead to sex bias in autism

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Monoclonal antibody nivolumab improves survival rates of melanoma patients

Novel discovery offers new insight into why women more likely than men to develop MS

UB researchers identify mechanisms behind some autistic behaviors, suggest potential targets

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News